Publications

Publications

Filter Results: (483) Arrow Down

Show Results For

← Page 7 of 483 Results →
  • Research Summary

Regulatory negotiations and risk communication

In the pharmaceutical industry a drugs benefits and risks are constantly being weighed by companies, regulators, physicians and drug consumers. While companies and regulators must make decisions based on population statistics about drug outcomes, physicians and drug... View Details
  • January 1996
  • Case

Biogen, Inc.: rBeta Interferon Manufacturing Process Development

By: Steven C. Wheelwright
Biogen, Inc., a Cambridge, MA-based biotechnology company, is wrapping up a project to develop a new manufacturing process for a new drug product that will reposition the company from a purely research-oriented company to a fully integrated pharmaceutical manufacturing... View Details
Keywords: Learning; Technological Innovation; Management Analysis, Tools, and Techniques; Product Development; Organizational Change and Adaptation; Projects; Research and Development; Corporate Strategy; Biotechnology Industry
Related
  • 14 Aug 2007
  • First Look

First Look: August 14, 2007

Behavioral research suggests that human learning in some multi-agent systems can be predicted with surprisingly simple "foresight-free" models. The current note discusses the implications of this research, and its relationship... View Details
Keywords: Martha Lagace

    Incentives for Bad Science

    Randomized controlled trials (RCTs) inform medical practice, health care delivery, follow-on research, regulation, and health policy. Yet, many RCTs are inadequately randomized, blinded, and reported. To analyze scientists' and firms' incentives to meet clinical trial... View Details
    • 21 Sep 2022
    • Research & Ideas

    You Don’t Have to Quit Your Job to Find More Meaning in Life

    meaningful life if you’re evil? But what if you cause harm? Is your life still considered meaningful? In a final experiment, the researchers examined the role of morality. Participants were told about Ariana, a fictional executive for a... View Details
    Keywords: by Shalene Gupta

      Robert S. Huckman

      Robert Huckman is the Albert J. Weatherhead III Professor of Business Administration at Harvard Business School, the Howard Cox Faculty Chair of the HBS Healthcare Initiative, and the Unit Head for View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

        Kyle R. Myers

        Kyle Myers is an assistant professor of business administration in the Technology and Operations Management unit. He teaches the first-year Technology and Operations Management course.

        Professor Myers studies the economics of innovation. His research is at... View Details

        Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
        • 15 May 2007
        • First Look

        First Look: May 15, 2007

        sociologists (and increasingly, economists) view networks to be essential to the functioning of markets, I will review much of the work that has been done in economic sociology on the formation of networks, as well as a little of the View Details
        Keywords: Martha Lagace

          Paul M. Healy

          Paul Healy is the James R. Williston Professor at the Harvard Business School. His research covers a broad range of topics, including white collar crime, governance, business ethics, financial analysis, and Wall Street research. He joined the HBS faculty in 1998,... View Details

          Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals

            Malcolm P. Baker

            Malcolm Baker is the Robert G. Kirby Professor of Business Administration at the Harvard Business School, where he teaches the required course in finance and a short immersive program on investing in life sciences.

            His research is in the... View Details

            Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
            • 10 Aug 2015
            • Research & Ideas

            New Medical Devices Get To Patients Too Slowly

            While the US Food and Drug Administration has chiseled away pharmaceutical review times over the years to speed innovative drugs to market, the opposite seems to have occurred in the agency's approval of medical devices. Instead of... View Details
            Keywords: by Michael Blanding; Health; Technology

              Gerald Zaltman

              *Joined Harvard Faculty: 1991
              Prior Faculty Appointments: Northwestern University, 1968-75;
              University of Pittsburgh, 1975-91

              *Doctoral Degree in Sociology Received from: The John Hopkins University;
              MBA Degree Received from: The University of... View Details

              Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
              • Research Summary

              The Transparency of Ethical Behavior

              (with Max Bazerman, Karim Kassam, and Neeru Paharia)
              This research analyzes how unethical behavior is viewed when performed... View Details

                Michael Beer

                MICHAEL BEER

                Mike Beer is the Cahners-Rabb Professor of Business Administration, Emeritus at the Harvard Business School and author Fit to Compete: Why Honest Conversations About Your Company’s... View Details

                • January 2014 (Revised December 2014)
                • Case

                GenapSys: Business Models for the Genome

                By: Richard G. Hamermesh, Joseph B. Fuller and Matthew Preble

                GenapSys, a California-based startup, was soon to release a new DNA sequencer that the company's founder, Hesaam Esfandyarpour, believed was truly revolutionary. The sequencer would be substantially less expensive—potentially costing just a few thousand dollars—and... View Details

                Keywords: DNA Sequencing; Life Sciences; Business Model; Innovation ＆ Entrepreneurship; Health Care and Treatment; Genetics; Business Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
                Related

                  Jay W. Lorsch

                  Jay W. Lorsch is the Louis Kirstein Professor of Human Relations at the Harvard Business School. He is editor of View Details

                  • 2010
                  • Working Paper

                  Accelerating Energy Innovation: Insights from Multiple Sectors

                  By: Rebecca Henderson and Richard G. Newell
                  A combination of concerns about climate change and energy security has recently led to significant increases in public funding for energy R&D. Some commentators are suggesting that these increases need to be sustained, and are advocating for increases of as much as... View Details
                  Keywords: Innovation and Management; Technological Innovation; Knowledge Use and Leverage; Research and Development; Pollutants; Climate Change; Energy Industry
                  Related

                    Krishna G. Palepu

                    KRISHNA G. PALEPU is the Ross Graham Walker Professor of Business Administration, and has served previously as Senior Advisor to the President of Harvard University, and Senior Associate Dean at the... View Details

                    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

                      Ranjay Gulati

                      Ranjay Gulati is the Paul R. Lawrence MBA Class of 1942 Professor of Business Administration and the former Unit Head of the Organizational Behavior Unit at Harvard Business School. His pathbreaking research, which focuses on unlocking organizational and unleashing... View Details

                      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

                        John A. Deighton

                        John Deighton is The Harold M. Brierley Professor of Business Administration Emeritus at Harvard Business School. He is an authority on consumer behavior and marketing, with a focus on digital and direct marketing. He teaches in the area of Big Data in Marketing,... View Details

                        Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals